Signal transduction via cannabinoid receptors.

Signal transduction via cannabinoid receptors.
复制标题

DOI:
10.2174/187152709789824615
复制
发表时间:
2009-12
期刊:
CNS & neurological disorders drug targets
影响因子:
--
通讯作者:
Howlett AC
Howlett AC
中科院分区:
其他
文献类型:
--
作者:
Dalton GD;Bass CE;Van Horn CG;Howlett AC

文献摘要

参考文献

被引文献

相似文献

The endocannabinoids anandamide and 2-arachidonoylglycerol (2-AG) are lipid mediators that signal via CB1 and CB2 cannabinoid receptors and Gi/o-proteins to inhibit adenylyl cyclase and stimulate mitogen-activated protein kinase (MAPK). In the brain, CB1 receptors interact with opioid receptors in close proximity, and these receptors may share G-proteins and effector systems. In the striatum, CB1 receptors function in coordination with D1 and D2 receptors, and combined stimulation of CB1-D2 receptor heteromeric complexes promotes a unique interaction to stimulate cAMP production. CB1 receptors also trigger growth factor receptor signaling cascades in cells by engaging in cross-talk or inter-receptor signal transmission with the receptor tyrosine kinase (RTK) family. Mechanisms for CB1 receptor-RTK transactivation can include stimulation of signal transduction pathways regulated by second messengers such as phospholipase C (PLC), metalloprotease cleavage of membrane-bound precursor proteins such as epidermal growth factor which activate RTKs, RTK autophosphorylation, and recruitment of non-receptor tyrosine kinases. CB1 and CB2 receptors are expressed in peripheral tissues including liver and adipose tissue, and are induced in pathological conditions. Novel signal transduction resulting from endocannabinoid regulation of AMP-regulated kinase (AMPK) and peroxisome proliferator-activated receptors (PPARs) have been discovered from studies of hepatocytes and adipocytes. It can be predicted that drug discovery of the future will be based upon these novel signal transduction mechanisms for endocannabinoid mediators.
DOI: 10.1172/jci200317725
发表时间: 2003-08-01
影响因子: 15.9
作者:
Cota, D;Marsicano, G;Pagotto, U
通讯作者: Pagotto, U
DOI: 10.1073/pnas.0509494102
发表时间: 2005-12-27
影响因子: 11.1
作者:
Berghuis, P;Dobszay, MB;Harkany, T
通讯作者: Harkany, T
DOI: 10.1016/s0376-8716(96)01320-8
发表时间: 1997-01-10
影响因子: 4.2
作者:
Bernstein, MA;Welch, SP
通讯作者: Welch, SP
DOI: 10.1016/j.ejphar.2004.06.009
发表时间: 2004-08-02
影响因子: 5
作者:
Bass, CE;Welch, SP;Martin, BR
通讯作者: Martin, BR
DOI: 10.1007/bf00426745
发表时间: 1978-01-01
期刊: PSYCHOPHARMACOLOGY
影响因子: 3.4
作者:
BLOOM, AS;DEWEY, WL
通讯作者: DEWEY, WL